High Intensity Laser Therapy

Class IV laser therapy devices were cleared in 2004 by the FDA for the safe and efficacious reduction of pain and increasing micro-circulation. Therapy lasers are safe and effective treatment options to reduce musculoskeletal pain due to injury. The biggest risk to injury during laser therapy treatments is to the eye, which is why certified, protective eyewear is always required during LightForce® treatments. LightForce Therapy is a safe Class IV device on the market, classified as IIa according to the EU medical devices classification, which have the lowest risk.

Based on peer-reviewed literature, there are no known significant side effects from LightForce therapy for most conditions. Most side effects are short-lived, typically lasting for up to a few hours. Understanding proper dosing parameters and the use of our Smart Handpiece minimize any potential side effects.

With LightForce® lasers, treatments are quick, average treatment time 4-7 minutes depending on the size, depth, and acuteness of the condition being treated. High-power lasers are able to deliver a lot of energy in a small amount of time, allowing therapeutic dosages to be achieved quickly. For patients and clinicians with packed schedules, fast and effective treatments are a must.

The nature of the condition and the patient’s response to the treatments will play a key role in determining how many treatments will be needed. Most laser therapy plans of care will involve 6-12 treatments, with more treatment needed for longer standing, chronic conditions.

Yes, it generally works well with other modalities that are designed to promote tissue repair. Best known examples are shockwave devices. The mechanisms that are associated with these modalities work well with LightForce therapy. Clinical proven benefits are being studied. Generally using modalities that are designed to provide cryotherapy, which generally reduce blood flow and promote vasoconstriction, are not recommended as adjunctive therapies with LightForce therapy.